NCT00312351

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

An Exploratory Randomized, Double-Masked, Multi-Center Comparative Trial, in Parallel Groups, to Explore the Safety and Efficacy of Three Different Doses of Intravitreous Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 102 Weeks, in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (AMD)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 262 (planned)
• Sponsor: Eyetech Pharmaceuticals · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.

Conditions

• Macular Degeneration

Interventions

Type	Name	Description
DRUG	Pegaptanib sodium

Timeline

• Start date: 2006-04-01
• Completion: 2006-11-01
• First posted: 2006-04-10
• Last updated: 2007-01-15

Locations

1 site across 1 country: United States